MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

Exclusion Criteria

• •Under 19 years of age.
• •Stent treatment failure lesions (stent restenosis or thrombosis).
• •Cardiac arrest or cardiogenic shock.
• •Currently taking or requiring strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-glycoprotein inhibitors (cyclosporine, ranolazine).
• •Presence of any of the following concomitant conditions: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia, severe gastrointestinal diseases, or genetic disorders such as galactose intolerance.
• •Hypersensitivity to colchicine treatment.
• •Currently taking colchicine for another condition.
• •Requiring anticoagulant therapy.
• •Liver disease classified as Child-Pugh class B or C.
• •Renal disease with creatinine clearance \<30 mL/min.
• •Pregnant, breastfeeding, or women of childbearing age.
• •Currently has a malignancy or has a history of malignancy within the past 5 years.
• •Life expectancy of less than 5 years.
• •Contraindication for ticagrelor use (history of intracranial hemorrhage, active pathological bleeding, or liver disease classified as Child-Pugh class B or C).
• •Patients receiving regular administration of systemic steroids, immunosuppressants, or biological agents (e.g., TNF-alpha inhibitors)
• •Patients with active infectious diseases